Daclatasvir plus asunaprevir for the treatment of patients with hepatitis C virus genotype 1b infection: Real-world efficacy, changes in liver stiffness and fibrosis markers, and safety

Hye Won Lee, Se Rim Oh, Dong Yun Kim, Yechan Jeong, Seungtaek Kim, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang Hyub Han, Jun Yong Park

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aims: The treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C virus (HCV) infection. We investigated the real-world efficacy, changes in liver stiffness and noninvasive fibrosis markers, and the safety of DCV+ASV treatment in Korean patients. Methods: In total, 363 patients with chronic hepatitis C were treated with DCV+ASV between August 2015 and January 2017. Finally, we analyzed the data of 270 patients who were monitored for at least 12 weeks after the end of treatment. Results: The mean age was 60.7 years, and females predominated (60.4%). Most patients (64.8%) were treatment-naïve, and 56 patients (20.7%) had cirrhosis. Two hundred fifty-seven (95.2%) and 251 (93.0%) patients achieved end-of-treatment responses and sustained virological responses at 12 weeks posttreatment (SVR12), respectively. The SVR12 rates were higher in patients who were <65 years of age, males, without cirrhosis and had lower HCV RNA levels. All LS values and fibrosis-4 and aspartate aminotransferase-to-platelet ratio index values declined from baseline to the time of assessment of SVR12. Conclusions: The DCV+ASV therapy resulted in a high SVR12 and improved liver fibrosis; the treatment was well tolerated in patients with genotype 1b HCV infections.

Original languageEnglish
Pages (from-to)324-330
Number of pages7
JournalGut and liver
Volume12
Issue number3
DOIs
Publication statusPublished - 2018 May

Fingerprint

Hepacivirus
Liver Cirrhosis
Genotype
Safety
Infection
Fibrosis
Therapeutics
Virus Diseases
BMS-790052
asunaprevir
Chronic Hepatitis C
Aspartate Aminotransferases
Antiviral Agents
Blood Platelets
RNA
Liver

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

@article{f53f176a05a445aca3b81f079382269a,
title = "Daclatasvir plus asunaprevir for the treatment of patients with hepatitis C virus genotype 1b infection: Real-world efficacy, changes in liver stiffness and fibrosis markers, and safety",
abstract = "Background/Aims: The treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C virus (HCV) infection. We investigated the real-world efficacy, changes in liver stiffness and noninvasive fibrosis markers, and the safety of DCV+ASV treatment in Korean patients. Methods: In total, 363 patients with chronic hepatitis C were treated with DCV+ASV between August 2015 and January 2017. Finally, we analyzed the data of 270 patients who were monitored for at least 12 weeks after the end of treatment. Results: The mean age was 60.7 years, and females predominated (60.4{\%}). Most patients (64.8{\%}) were treatment-na{\"i}ve, and 56 patients (20.7{\%}) had cirrhosis. Two hundred fifty-seven (95.2{\%}) and 251 (93.0{\%}) patients achieved end-of-treatment responses and sustained virological responses at 12 weeks posttreatment (SVR12), respectively. The SVR12 rates were higher in patients who were <65 years of age, males, without cirrhosis and had lower HCV RNA levels. All LS values and fibrosis-4 and aspartate aminotransferase-to-platelet ratio index values declined from baseline to the time of assessment of SVR12. Conclusions: The DCV+ASV therapy resulted in a high SVR12 and improved liver fibrosis; the treatment was well tolerated in patients with genotype 1b HCV infections.",
author = "Lee, {Hye Won} and Oh, {Se Rim} and Kim, {Dong Yun} and Yechan Jeong and Seungtaek Kim and Kim, {Beom Kyung} and Kim, {Seung Up} and Kim, {Do Young} and Ahn, {Sang Hoon} and Han, {Kwang Hyub} and Park, {Jun Yong}",
year = "2018",
month = "5",
doi = "10.5009/gnl17298",
language = "English",
volume = "12",
pages = "324--330",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "3",

}

Daclatasvir plus asunaprevir for the treatment of patients with hepatitis C virus genotype 1b infection : Real-world efficacy, changes in liver stiffness and fibrosis markers, and safety. / Lee, Hye Won; Oh, Se Rim; Kim, Dong Yun; Jeong, Yechan; Kim, Seungtaek; Kim, Beom Kyung; Kim, Seung Up; Kim, Do Young; Ahn, Sang Hoon; Han, Kwang Hyub; Park, Jun Yong.

In: Gut and liver, Vol. 12, No. 3, 05.2018, p. 324-330.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Daclatasvir plus asunaprevir for the treatment of patients with hepatitis C virus genotype 1b infection

T2 - Real-world efficacy, changes in liver stiffness and fibrosis markers, and safety

AU - Lee, Hye Won

AU - Oh, Se Rim

AU - Kim, Dong Yun

AU - Jeong, Yechan

AU - Kim, Seungtaek

AU - Kim, Beom Kyung

AU - Kim, Seung Up

AU - Kim, Do Young

AU - Ahn, Sang Hoon

AU - Han, Kwang Hyub

AU - Park, Jun Yong

PY - 2018/5

Y1 - 2018/5

N2 - Background/Aims: The treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C virus (HCV) infection. We investigated the real-world efficacy, changes in liver stiffness and noninvasive fibrosis markers, and the safety of DCV+ASV treatment in Korean patients. Methods: In total, 363 patients with chronic hepatitis C were treated with DCV+ASV between August 2015 and January 2017. Finally, we analyzed the data of 270 patients who were monitored for at least 12 weeks after the end of treatment. Results: The mean age was 60.7 years, and females predominated (60.4%). Most patients (64.8%) were treatment-naïve, and 56 patients (20.7%) had cirrhosis. Two hundred fifty-seven (95.2%) and 251 (93.0%) patients achieved end-of-treatment responses and sustained virological responses at 12 weeks posttreatment (SVR12), respectively. The SVR12 rates were higher in patients who were <65 years of age, males, without cirrhosis and had lower HCV RNA levels. All LS values and fibrosis-4 and aspartate aminotransferase-to-platelet ratio index values declined from baseline to the time of assessment of SVR12. Conclusions: The DCV+ASV therapy resulted in a high SVR12 and improved liver fibrosis; the treatment was well tolerated in patients with genotype 1b HCV infections.

AB - Background/Aims: The treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C virus (HCV) infection. We investigated the real-world efficacy, changes in liver stiffness and noninvasive fibrosis markers, and the safety of DCV+ASV treatment in Korean patients. Methods: In total, 363 patients with chronic hepatitis C were treated with DCV+ASV between August 2015 and January 2017. Finally, we analyzed the data of 270 patients who were monitored for at least 12 weeks after the end of treatment. Results: The mean age was 60.7 years, and females predominated (60.4%). Most patients (64.8%) were treatment-naïve, and 56 patients (20.7%) had cirrhosis. Two hundred fifty-seven (95.2%) and 251 (93.0%) patients achieved end-of-treatment responses and sustained virological responses at 12 weeks posttreatment (SVR12), respectively. The SVR12 rates were higher in patients who were <65 years of age, males, without cirrhosis and had lower HCV RNA levels. All LS values and fibrosis-4 and aspartate aminotransferase-to-platelet ratio index values declined from baseline to the time of assessment of SVR12. Conclusions: The DCV+ASV therapy resulted in a high SVR12 and improved liver fibrosis; the treatment was well tolerated in patients with genotype 1b HCV infections.

UR - http://www.scopus.com/inward/record.url?scp=85048705634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048705634&partnerID=8YFLogxK

U2 - 10.5009/gnl17298

DO - 10.5009/gnl17298

M3 - Article

C2 - 29409309

AN - SCOPUS:85048705634

VL - 12

SP - 324

EP - 330

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 3

ER -